Table 2

Associations between the A2 allele and breast cancer risk by histological subtype and receptor status

CYP17 genotypeORaAdjusted ORb
A1/A1 n (%)A1/A2 + A2/A2 n (%)
Controls217 (35)401 (65)1.01.0
Cases
 Invasive145 (37)242 (63)0.90 (0.69–1.18)0.90 (0.68–1.19)
 Involved nodes
  ≥140 (37)67 (63)0.91 (0.59–1.41)0.84 (0.54–1.32)
  ≥414 (39)22 (61)0.80 (0.39–1.62)0.77 (0.37–1.61)
Receptor statusc
 ER+d98 (37)166 (63)0.91 (0.67–1.23)0.91 (0.66–1.24)
 ER−27 (42)37 (58)0.76 (0.44–1.29)0.74 (0.43–1.29)
 PR+75 (37)128 (63)0.91 (0.65–1.27)0.92 (0.66–1.30)
 PR−45 (39)68 (61)0.84 (0.55–1.28)0.79 (0.51–1.23)
  • a Unconditional logistic regression adjusted for matching variables: age, menopausal status, postmenopausal hormone use, date of blood draw, time of blood draw, and fasting status.

  • b Unconditional logistic regression adjusted for matching variables, and age at menarche, parity, age at first birth, BMI at age 18, weight gain since age 18, benign breast disease, first-degree family history of breast cancer, and duration of postmenopausal hormone use.

  • c Numbers do not add to total due to missing data on receptor status.

  • d ER, estrogen receptor; PR, progesterone receptor.